Potential best-in-class lead program targets Nav1.8, a validated human target for pain THOUSAND OAKS, Calif., Feb. 14, 2024 /PRNewswire/ — Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.